A hollow body includes a wall which at least partially surrounds an interior volume of the hollow body. The wall comprises a layer of glass comprising a first glass composition, comprises a base surface, and has a wall surface. The wall surface comprises at least one surface region, in which the base surface is at least partially superimposed by at least one elevated region, and at least one contact region, which extends along a contact range of a height of the hollow body. The at least one elevated region comprises a further glass composition. An exterior diameter of the hollow body has a maximum throughout the contact range. The at least one surface region is at least partially positioned in the at least one contact region.

A freeze/thaw containment system is provided, having a protecting body and a flexible pouch protected by two plates of the protecting body. The two plates are attached together at a peripheral margin and form a rectangular protecting body. The peripheral margin is mounted in supporting parts of a stationary frame and sliding positioning members are secured to the peripheral margin, so that the peripheral margin is guided and allowed to be displaced inwardly during filling of the pouch, while the protecting body extends generally planar to sandwich and constrain the pouch in empty state of the pouch. This way of holding and retaining the protecting body allows for progressive conformational change of the protecting body due to the change in volume of the pouch when filled with a biopharmaceutical product, while facilitating reverse displacement of the peripheral margin during draining operations.

A port includes a conduit configured to receive a spike therein. The conduit includes a first portion, a second portion, and a septum fluidly separates the first portion and the second portion of the conduit. The septum is puncturable by the spike so as to allow the spike to be inserted into the second portion of the conduit. A removable snap portion extends from a break point to the tip of the port. The thickness of the break point is less than the thickness of the remainder of the conduit wall. The removable snap portion is configured to break away from the port at the break point such that the septum is accessible by the spike via the first portion of the conduit when the removable snap portion is broken away from the port. The port may include fluorinated ethylene propylene, ethylene tetrafluoroethylene, perfluoroalkoxy alkane, and combinations thereof.

The purpose of the present invention is to provide a resin composition for manufacturing a medical storage container that has improved oxygen permeability and that tends not to have excessively lower transparency. To this end, the present invention pertains to a resin composition for manufacturing a medical storage container, the composition including polyethylene (a) and polymethylpentene (b). The resin composition contains, as polyethylene (a), a first polyethylene (a-1), which is a main component of the polyethylene (a), and a second polyethylene (a-2) having a lower density than the first polyethylene.

Provided herein are containers comprising a composition comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. The containers can be bottles or vials, for example, glass or polyethylene terephthalate G (PETG) bottles or vials. Also provided are kits comprising the containers and methods of treating cancer using the antibodies from the containers.

A liquid formulation of an ophthalmic drug in a pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer.

A method for improving the efficiency of a pharmaceutical filling line by running the filling line at an increased throughput rate is disclosed. The method involves using glass vials that have been strengthened and coated to reduce the coefficient of friction of the outer surface of the vials with a pharmaceutical filling line set at a rate greater than or equal to 600 vials per minute and miming in an efficiency of at least 70%. In other embodiments of the invention, the pharmaceutical filling line may also be provided with a polymer chemical coating at points of contact with the glass vials, thereby further reducing the friction between the vials and the points of contact and the effects of impact of the vials with contact points of the pharmaceutical filling line.

The eye drop container includes a container body having an inner plug and an opening part in which the inner plug is mounted. The inner plug is mounted in the opening part of the container body, constitutes a nozzle part, and has a liquid-contacting part which is constituted of a layer including a cyclic olefin copolymer, a cushioning part which is provided in an outer circumferential part in contact with the opening part, a flange part which comes into contact with a tip surface of the opening part, and a leg part which comes into contact with an inner surface of the opening part. The cushioning part is provided on at least an outer circumferential surface of the leg part.

Provided are ready to use drip bags of dilute noradrenaline having improved stability in terms of subvisible particle formation.

Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.